Bertis Pan-omics Analysis Solution, Systems (PASS) launched in US

Bertis, a company specializing in the development of proteomics-based precision medicine technology , announced on Monday the launch of PASS (Pan-omics Analysis Service & Solution) service in the United States through its wholly owned US subsidiary, Bertis Bioscience Inc.

Pan-omics is the integration of complex “omics” datasets generated from the subfields of genomics, transcriptomics, proteomics, and metabolomics to increase the understanding of pathophysiology, diagnosis, and treatment of diseases.

PASS is an insightful analysis solution leveraging Bertis’ pan-omics knowledge and know-how coupled with its proprietary bioinformatics and AI technology to deliver analytical services including the core protein identification and biomarker discovery but also drug development and clinical research processes.

In the US, Bertis’ wholly owned US subsidiary, Bertis Bioscience, has launched the much-anticipated PASS services after more than a year of preparation to assemble industry recognized experts in both mass spec-based proteomics as well as bioinformatics. 

The US PASS services will be provided at its CLIA Lab in San Diego. As part of the US PASS offerings, Bertis Bioscience will initially offer proof-of-principle studies for protein biomarker discovery using Seer’s proteograph and nanoparticle kits.

On June 8, 2023, Bertis Biosciences signed its first proteomics-based analysis service agreement in the United States with the Salk Institute for Biological Studies, a San Diego-based non-profit life science research center.

The Salk Institute is known for life-changing discoveries in the fields of cancer, neuroscience, aging, immunobiology, and plant biology. Six Nobel Prize winners conducted research at Salk, one of the world's leading research centers. Under this agreement, Bertis Bioscience will provide proteomic data analysis to look for novel human disease biomarkers.

"We are pleased with the market’s enthusiastic reception of our PASS service launched just last year.  We attribute the success to the market’s recognition of Bertis’ proprietary technology and know-how in proteomics analysis and commercialization. Our technology and services have shown strong global competitiveness and receive favorable reception at various international conferences.  We believe the US will provide a stage for us to showcase our expertise globally and build our PASS business by serving world-class research institutions as a start,” said Seung-man Han, CEO of Bertis. 

Amid the increasing demand for multi-omics analysis data, PASS has received significant attention from industries such as biotech, pharmaceutical companies, and research institutes since its launch in South Korea in May 2022.

Leveraging its state-of-the-art analysis system and industry leading proteomics expertise, as of June, Bertis Inc. signed agreements for PASS with twenty companies, including national institutions, government-funded research institutes, and private companies as of June this year.

Write to Woo-Sang Lee at idol@hankyung.com